Description
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
Location: CPMC (San Francisco)
Please contact: ClinicalResearch@sutterhealth.org about study Moderna Keynote 942